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Consumption of sufficient quantities of oat products has been shown to reduce host
cholesterol and thereby modulate cardiovascular disease risk. The effects are proposed
to be mediated by the gel-forming properties of oat β-glucan which modulates host
bile acid and cholesterol metabolism and potentially removes intestinal cholesterol
for excretion. However, the gut microbiota has emerged as a major factor regulating
cholesterol metabolism in the host. Oat β-glucan has been shown to modulate the gut
microbiota, particularly those bacterial species that influence host bile acid metabolism
and production of short chain fatty acids, factors which are regulators of host cholesterol
homeostasis. Given a significant role for the gut microbiota in cholesterol metabolism it is
likely that the effects of oat β-glucan on the host are multifaceted and involve regulation
of microbe-host interactions at the gut interface. Here we consider the potential for oat
β-glucan to influence microbial populations in the gut with potential consequences for
bile acid metabolism, reverse cholesterol transport (RCT), short-chain fatty acid (SCFA)
production, bacterial metabolism of cholesterol and microbe-host signaling.
Keywords: microbiome, microbiota, oat beta glucan, bile, propionate, cholesterol
INTRODUCTION
A significant body of evidence demonstrates that consumption of oat products is linked to a
reduction in serum LDL cholesterol, a risk factor for the development of cardiovascular disease
(CVD) (1–3). Oats are a source of soluble fiber in the form of β-glucan (as well as arabinoxylan,
xyloglucan, and other minor components), insoluble fiber, protein, lipids, phenolic compounds,
vitamins, and minerals. Whilst other constituents in oats may also have an impact, the cholesterol-
lowering activity of oats has been demonstrated to be associated with an increase in viscosity of
the gut contents (4) which enhances excretion of bile acids and cholesterol in the feces (5). Indeed,
consumption of β-glucan alone can reduce serum cholesterol (6). The weight of evidence in support
of a beneficial role of oat β-glucans led the US Food and Drug Administration (FDA) to authorize
the use of health claims on oat products attributing lowering of CVD risk to consumption of at
least 3 g per day of β-glucan. Cholesterol lowering claims have also been approved in the EU by the
European Commission (7–9) and in a number of other jurisdictions including Australia and New
Zealand (10), Canada (11), Brazil (12, 13), Malaysia (14), Indonesia (15), and South Korea (16).
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We, and others, consider that the cholesterol-lowering
properties of oats may not be solely attributable to the viscous
properties of β-glucans (17–19). Recent research suggests a
significant role for the gut microbiota in the maintenance of
cholesterol homeostasis in the host (20). A number of studies
have demonstrated the efficacy of probiotics [in particular,
probiotic strains with an ability to metabolize host bile acids
through bacterial bile salt hydrolase (BSH) activity] in lowering
cholesterol in animal models or in humans (21–25). Microbial
metabolism of bile acids is known to influence systemic
cholesterol metabolism. As cholesterol is a precursor of bile acids,
influencing bile acid synthesis provides a means for enhanced
excretion of cholesterol thereby lowering serum cholesterol levels
in the host (26, 27). Bile acid signaling through the farnesoid
X receptor (FXR) and other receptors may also influence host
metabolism of cholesterol, for example through the induction
of cholesterol transport in the gut (27, 28). Alterations to
microbial production of short chain fatty acids (SCFA) including
propionate are also likely to have consequences for cholesterol
metabolism in the host (29), though the precise mechanisms
remain to be elucidated (30). Importantly, oat products and oat
β-glucans have been shown to modulate the gut microbiota in
human, animal and in vitro fermentation systems (19, 31, 32).
Therefore, oats (including oat β-glucans) may have a dietary
influence upon the host gut microbiota with consequences for
bile acid signaling, SCFA signaling, and other effects that are
known modulators of host cholesterol homeostasis.
Herein we review the evidence linking components of
oats with alterations to host microbiota and discuss potential
mechanisms by which such microbiota changes may influence
host cholesterol metabolism with a particular focus upon bile
acid metabolism. Whilst we appreciate that oat β-glucans may
also play a role in post-prandial glucose homeostasis (33) in
this review we will predominately focus upon mechanisms by
which they lower host cholesterol. Our focus is primarily on
the effects of oat β-glucans. However, some reference will be
made to the mechanistic effects of barley β-glucans, notably in
instances where relevant studies have not yet been performed
using oat β-glucans.
CLINICAL EVIDENCE FOR
CHOLESTEROL-LOWERING PROPERTIES
OF OATS
A large number of individual randomized-controlled trials and
subsequent meta-analyses have established a significant effect
of consumption of oats or oat β-glucans in reducing LDL
cholesterol and improving other markers of cardiovascular
disease (CVD) risk (1–3, 34). A meta-analysis of 126 individual
studies by Tiwari and Cummins (1) examined the effect of β-
glucan intake on measures of blood cholesterol [total cholesterol
(TC) and low-density lipoprotein (LDL)-cholesterol] as well
as blood glucose levels. The study demonstrated a significant
reduction of TC (by 0.6 mmol/L), LDL cholesterol (by 0.66
mmol/L), and TGL/TAG (by 0.04 mmol/L) and an increase in
HDL cholesterol (by 0.03 mmol/L) following consumption of
oat or barley β-glucan (oat and barley β-glucans are considered
bioequivalent with respect to cholesterol-lowering properties). A
dose response model demonstrated a decrease in TC with an
increase in β-glucan dose but no increased effect in individuals
consuming over 3 g/day β-glucan (1). This finding supports FDA
recommendations relating to consumption of 3 g/day β-glucan to
lower CVD risk (35).
Similarly a meta-analysis of randomized-controlled trials by
Whitehead et al. which focused upon consumption of ≥3 g/day
oat β-glucan showed a significant reduction in both TC (by 0.30
mmol/L) or LDL cholesterol (by 0.25 mmol/L) (but no effect on
HDL cholesterol or TGL) (2). The study found no increased effect
in those consuming higher doses of β-glucan, again suggesting
that a minimum recommended dose of 3 g/day is sufficient
for the cholesterol-lowering effect and is not enhanced through
consumption of higher doses.
AbuMweis et al. (36) combined the data from 11 randomized-
controlled trials that fitted their weighted criteria based on
dose, duration, source of β-glucan, population characteristics and
sample size to report that interventions did elicit changes in total
and LDL cholesterol levels relative to control subjects, but no
dose-response was observed. Reductions in TC of 0.30 mmol/L
and reductions in LDL cholesterol of 0.27 mmol/L were reported
in response to consumption of ≥3 g/day barley β-glucan.
The lack of a dose-response when consuming levels of β-
glucan>3 g/day was noted above. This lack of dose response may
reflect variation in the physico-chemical properties of β-glucans
used in individual randomized-controlled trials and included in
the above meta-analyses. It is known that highly water soluble
β-glucan of medium to high average molecular weight (Mw) is
more effective in reducing serum cholesterol than poorly water
soluble β-glucan of low Mw (37). However, the precise Mw of
β-glucan can be difficult to establish and may not be accurately
reported in randomized-controlled trial data (2). It has also been
suggested that the individual food matrix and/or food processing
procedures may influence the Mw (and therefore bioactivity)
of β-glucan and that this is a further confounding factor when
comparing data from individual trials (2). The influence of so
many variables may suggest that particular meta-analyses are
not sufficiently powered to detect a dose-effect when comparing
studies which use differing forms of β-glucan with variations in
viscosity and bioactivity where such parameters remain unknown
(2, 36).
BILE ACID SYNTHESIS IN THE HOST
Bile acid synthesis and excretion is the main route by which
cholesterol is effectively eliminated from the body. In the
following sections we provide a basic overview of bile acid
metabolism in the host with a particular emphasis upon how
the gut microbiota contributes to metabolism of the bile acid
pool. These concepts are further expanded in sections Alterations
to Gut Microbiota and Effects on Cholesterol Metabolism
and Mechanisms by Which Oat β-Glucan may Influence Host
Cholesterol Metabolism Through Alterations in BSH Activity of
the Microbiome below.
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The Bile Acid Cycle, Cholesterol, and the
Role of Microbial BSH
Bile acids are synthesized in liver hepatocytes from cholesterol
by cytochrome enzymes (CYPs). Approximately 500mg of
cholesterol is converted to bile acid (BA) on a daily basis (38).
Prior to secretion and storage in the gall bladder primary bile
acids chenodeoxycholic acid (CDCA) and cholic acid (CA) are
conjugated to either a taurine or a glycine molecule to aid
their solubility and excretion from the liver. The majority of
conjugated bile acids are reabsorbed in the terminal ileum, with
5% excreted in the feces [see (39) for a review]. Conjugated
bile acids are released postprandially from the gall bladder into
the small intestine and are subject to enzymatic modifications
by the bile salt hydrolase (BSH) activity of the microbiota
to liberate them from their cognate amino acid. This renders
them susceptible to further microbial modification to form
secondary bile acids lithocholic acid (LCA) from CDCA and
deoxycholic acid (DCA) from CA. This activity is completed by
specificmembers of the colonic microbiota [the Eubacterium and
Clostridium XIVa clusters (40)] although gene analyses suggest
that other microbial representatives may be capable of carrying
out these reactions [reviewed by Long et al. (39)]. Therefore,
while the liver dictates bile acid production, the gut microbiota
is responsible for the diversity of BAs derived from the bile
acid CA and CDCA families and it also influences reuptake or
enterohepatic circulation. Alterations to the range and relative
profile of bile acids is a reliable readout of microbial changes in
the gut and such changes are particularly evident in disease states
including metabolic syndrome, inflammatory bowel diseases
and Type II diabetes [see (41, 42) for reviews]. Therefore, the
dietary effects of oat β-glucan on the microbiota (outlined in
section Alterations to Gut Microbiota and Effects on Cholesterol
Metabolism), are likely to impact bile acid profiles in the host
with potential consequences for metabolism and signaling.
Bile acids are ligands for the farnesoid-X-receptor (FXR)
which is a nuclear receptor that is central to energy andmetabolic
regulation in a range of different tissues (43). Microbially-
modified and unconjugated bile acids are the most potent natural
FXR ligands with CDCA < LCA< DCA< CA in order of
affinity and activation strength, while ursodeoxycholate (UDCA)
and murine tauro-β-muricholic acid can hinder FXR activity
(27, 44, 45). FXR is widely distributed in tissues including the
intestine and the liver. FXR therefore acts as a bile acid sensor in
the intestine and as a controller of bile acid synthesis in the liver
(46). It controls bile acid synthesis by a variety of mechanisms.
Agonism of FXR in the intestine induces production of the
endocrine hormone fibroblast-growth-factor 19 [FGF19 (in
humans) FGF15 (in mice)] which enters the circulation and
activates specific receptors on hepatocytes to reduce bile acid
synthesis (through down-regulation of a key enzyme CYP7A1)
(47–49). Alternatively a reduction in engagement of the FXR
may enhance expression of regulatory networks that are inhibited
by FXR such as the liver orphan receptor (LXR) regulon
(24). Another layer of cross-talk from the intestine to the
liver acts through enterohepatic re-circulation of bile acids. On
reaching the liver, circulating bile acids activate FXR directly to
ultimately inhibit CYP7A1 transcription, again reducing bile acid
synthesis (44).
The importance of FXR in host cholesterol metabolism is
highlighted by studies using FXR knock-out mice or specific
chemical agonists of the FXR [reviewed in Li and Chiang (27)].
Knock-out of FXR in mice results in elevated LDL-C (50),
whereas stimulation of the FXR in hypercholesterolaemic mice
(using bile acids or specific agonists) results in a lowering of
HDL-C and LDL-C (51). More recently, the intestinal FXR
agonist Fexaramine (Fex) was shown to induce FGF15 and to lead
to broadly beneficial metabolic effects including reduced weight
gain inmice fed a high fat diet (52) and reduced serum cholesterol
in a mouse model of diabetes (53). The precise mechanisms by
which FXR contributes to cholesterol metabolism in the host
remain unclear but are thought to involve regulation of fatty acid
metabolism as well as Reverse Cholesterol transport (RCT) and
Trans-intestinal Cholesterol excretion (TICE) (outlined below)
(27, 54).
Reverse Cholesterol Transport (RCT) and
Trans-intestinal Cholesterol Excretion
(TICE)
In addition to the incorporation of cholesterol into bile acids and
subsequent bile acid excretion, other mechanisms contribute to
the systemic control of host cholesterol. RCT is a mechanism
for directly transporting cholesterol from the tissues to the
liver for excretion into bile, and ultimately in feces. RCT relies
upon cholesterol loading onto HDL particles which can remove
cholesterol from the tissues, notably frommacrophage foam cells
in the artery wall [reviewed in Temel and Brown (55) and Tall and
Yvan-Charvet (56)]. HDL-cholesterol then enters hepatocytes via
specific receptors and the cholesterol is secreted directly into
bile for excretion via the specific transporters ABCG5/G8. This
represents a mechanism by which HDL-cholesterol is thought to
be associated with reduced cardiovascular disease risk.
More recent work has revealed a supplemental system
for Trans-intestinal cholesterol excretion (TICE) directly into
feces through enterocytes in the proximal small intestine. The
model proposes that cholesterol is removed from HDL particles
in the liver and loaded onto ApoB-containing lipoproteins
which migrate to the small intestine where the particles are
transported across enterocytes and the cholesterol is excreted
into the intestinal lumen. Again cholesterol excretion is via
the ABCG5/G8 transport system, in this case expressed in
enterocytes (55). Importantly genes that encode essential
components of both RCT and TICE are regulated via FXR (27).
These include ApoA1 which encodes a component of HDL
particles and the ABCG5/G8 transport system (28). This suggests
that bile acid signals (and therefore the microbiota) canmodulate
both RCT and TICE (section Mechanisms by Which Oat β-
Glucan May Influence Host Cholesterol Metabolism Through
Alterations in BSH Activity of the Microbiome below).
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THE VISCOUS NATURE OF β-GLUCAN
AND EXISTING PROPOSED MECHANISM
FOR CHOLESTEROL-LOWERING
The β-glucan polysaccharide forms a viscous liquid suspension
in solution, a characteristic which is predicted to occur
under physico-chemical conditions encountered in the GI
tract. Intestinal viscosity of β-glucan is determined by its
concentration, solubility and Mw, features that may influence
variation in clinical effects seen across different controlled
trials. Indeed, recent studies have determined the effects of
increasing viscosity upon physiological efficacy. In a large
randomized controlled trial the capacity of oat products to
lower serum cholesterol was directly proportional to the Mw
of the β-glucan component, with high (2.2 million g/mol)
and medium (850,000 g/mol or 530,000 g/mol) Mw β-glucans
significantly reducing LDL cholesterol and a low (210,000
g/mol) Mw β-glucan proving ineffective (4). Furthermore
both increasing viscosity (57) or increasing Mw (58) of β-
glucan have been shown to increase the ability to regulate
post-prandial glucose concentrations in human subjects. The
beneficial effects of high Mw oat β-glucan are therefore thought
to be related to an ability to form a viscous solution in
the intestine.
The mechanisms by which viscous β-glucans modulate
host cholesterol are thought to be linked to modulation
of host bile acid metabolism (59). Viscous β-glucan is
hypothesized to interact with bile acids and prevent their re-
adsorption in the terminal ileum. This results in increased
fecal excretion of bile acids thereby increasing the requirement
for de novo synthesis of bile acids from cholesterol, a
mechanism which lowers systemic LDL cholesterol (59). In
support of this, a number of animal studies (60, 61) and
human intervention studies have shown elevated fecal bile
acid excretion following consumption of oats or β-glucan (5,
62–64). This is matched by evidence for elevated de novo
bile acid synthesis following consumption of oats both in
animals (through measurement of activity of relevant liver
enzymes including Cyp7A1) (61) or through measurement of
7 alpha-hydroxy-4-cholesten-3-one (HC) in humans (a marker
for bile acid synthesis) (61, 64). A comprehensive study in
pigs demonstrated that oat β-glucan feeding increased bile
acid excretion during the early feeding period but that bile
acid excretion actually decreased in this group following
dietary adaptation. The study pointed to alterations in gut
physiology, reduced bile acid uptake, and a reduction in
cholesterol absorption along with possible microbiota changes
that could explain the reduction in systemic cholesterol levels
in the β-glucan-fed group (65). The authors indicated that
oat β-glucan significantly influenced bile acid and cholesterol
metabolism in the host along with a likely beneficial (prebiotic)
effect on the gut microbiota which enhanced both the
generation of the secondary bile acid UDCA and cholesterol
digestion in the gut (65). The possible effects of such
microbiota-mediated mechanisms are outlined further in the
sections below.
ALTERNATIVE MECHANISMS BY WHICH
OAT β-GLUCAN MAY AFFECT HOST
CHOLESTEROL METABOLISM
Alterations to Gut Microbiota and Effects
on Cholesterol Metabolism
Whilst the precise mechanisms remain to be elucidated it is clear
that the gut microbiota plays a significant role in host cholesterol
homeostasis. Very early studies indicate that antibiotic treatment
of mice inhibits cholesterol metabolism leading to accumulation
of systemic cholesterol (66). Also, germ-free rats accumulate
greater levels of cholesterol from elevated cholesterol diets
compared to conventionally raised animals (67). Germ free rats
demonstrated lower levels of systemic catabolism of dietary
cholesterol (68) and also showed reduced fecal excretion of both
total sterols and bile acids in particular (69). The data suggest
that increased bile acid synthesis from cholesterol is a mechanism
for lowering of systemic cholesterol levels (68) and is influenced
by the activities of the gut microbiota. Furthermore, there is
significant evidence that transient alteration of the microbiota
through the administration of probiotic bacteria can be beneficial
in lowering of systemic cholesterol (see sections below). The
data suggest a role for the microbiota in the maintenance of
cholesterol homeostasis in the host and suggest that alteration
of the community structure of this microbial population has
the capacity to influence cholesterol metabolism (70). More
detailed studies are necessary in order to pinpoint specific
microbial genera or species in the gut which may influence host
cholesterol metabolism. Such information is emerging for models
of lipid metabolism, weight gain and adiposity. For instance,
murine studies pointed to alterations in the relative ratios of
two major phyla, Bacteroidetes, and Firmicutes in promoting
weight gain (71, 72). The findings also correlated with human
studies in obese volunteers subjected to a calorie-restricted diet
(73) and the obesity phenotype was transferable by transplant
of the microbiota from either obese mice or obese humans to
microbiota naïve mice, thereby showing a functional role of
the microbiota in this phenomenon (74–76). Other studies have
shown a clear link betweenmicrobial gene richness andmetabolic
health. Individuals with low gene richness in the microbiota are
more likely to display increased adiposity and dyslipidemia (77).
β-glucan is resistant to depolymerization by gastric and
pancreatic enzymes and transits to the colon for microbial
fermentation. Alteration of bile acid metabolism is also known
to impact the microbiota (78) and is therefore a further
possible mechanism by which β-glucans may modulate microbial
gut populations.
There is significant evidence from models of increasing
complexity (from in vitro fermentation models, to rodent to
porcine models) and human intervention studies that oat fibers
have a significant impact upon the compositional structure
of the gut microbial community. For critical reviews of the
effects of β-glucan upon the microbiota the reader is referred
to Jayachandran et al. (79) and Sanders et al. (80). Relatively
simple in vitro fermentation studies which mimic the human
colon using human fecal bacterial populations allow for highly
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controlled analyses of bacterial responses to dietary components
but lack the biological complexity of in vivo models. In
vitro fermentation studies have shown that addition of oat or
barley β-glucan directly promotes the growth of gut bacterial
populations (including the Clostridium histolyticum subgroup
and Bacteroidetes/Prevotella groups) (81). A recent study using
an in vitro batch culture system demonstrated that oat β-glucan
induced proliferation of Bacteroidetes but was not Bifidogenic. In
contrast growth of Bifidobacteria was stimulated by oat-derived
polyphenols (82). In another study oat flakes promoted growth
of the Bacteroides/Prevotella group or Bifidobacterium group in
a fecal slurry with effects related to the size of the oat flakes
(31). A recent study indicates the ability of oat β-glucan to
promote growth of Prevotella and Roseburia species in an in
vitro fermentation with concomitant production of the short
chain fatty acids (SCFA) propionate and butyrate (83). Overall
these studies indicate that oat β-glucan and other components
of whole oats can influence populations of biologically relevant
bacterial taxa.
Recent studies in mice demonstrated that oat β-glucan feeding
increases populations of Bacteroides species and Prevotella
species whereas bacteria from the phylum Firmicutes were
decreased (84). Zhou et al. similarly showed that whole
grain oat flour causes significant alterations to microbiota
community structure relative to a control diet with alterations
to Prevotellaceae, Lactobacillaceae, and Alcaligenaceae families
(85). Importantly the microbiota changes correlated with a
significant lowering of total cholesterol and non-HDL cholesterol
in animals fed whole grain oat flour (85). Ryan et al. showed a
significant reduction in markers of cardiovascular disease risk
in an apoE deficient mouse model following feeding with oat
β-glucans which correlated with an increase in the population
of the family Verrucomicrobia and elevated production of n-
butyrate (32). This is particularly interesting as Akkermansia
muciniphila (a key member of the Verrucomicrobia) has been
functionally linked to improved gut barrier function, reduction in
obesity, and improved metabolic health (86). Early studies in rats
utilized a culture-based approach and demonstrated that feeding
of oat flour formulations led to an increase in Bifidobacteria
populations in the gut (87). Insoluble high viscosity oat β-glucan
enriched for Clostridium cluster I in a pig model with associated
increases in butyrate production (88).
When microbial composition studies were performed in
humans, low Mw barley β-glucan did not appear to alter
microbial representation however high Mw barley β-glucan was
associated with higher levels of the phylum Bacteroidetes while
Firmicutes levels were reduced (89). These alterations were
accompanied by reductions in CVD risk factors including BMI,
blood pressure and circulating triacylglycerol (TAG) over the 35-
day study period and the authors identified specific microbial
taxa whose abundance correlated with markers of disease risk
(including total cholesterol and LDL-C) (89). Another study
used fluorescence in situ hybridization with probes specific for
selected bacterial genera and showed that consumption of an oat-
based granola breakfast cereal was associated with a cholesterol-
lowering effect concomitant with elevated Bifidobacterium and
Lactobacillus species. As these species are associated with BSH
activity and as members of these species have been previously
used as probiotics which can lower serum cholesterol levels,
the authors suggested that the lowering of serum cholesterol in
this study may be linked to alterations to bile acid metabolism
and that further studies are warranted. No significant changes
were seen in particular species of Bacteroides, Atopobium, or
Clostridium targeted in this study (19).
Overall, intervention studies utilizing sources of β-glucan
suggest that consumption can promote alterations to the gut
microbiota with some studies suggesting a potentially beneficial
(prebiotic) effect (19).
Mechanisms by Which Oat β-Glucan may
Influence Host Cholesterol Metabolism
Through Alterations in BSH Activity of the
Microbiome
Evidence from in vitro fecal fermentation studies and rodent
and human intervention studies suggest that oat β-glucan
consumption increases levels of bacteria in the gut with known
BSH activity (reviewed above).
A variety of studies have demonstrated an elevation of
Bifidobacterium, Bacteroides, and Lactobacillus species in the
gut following oat β-glucan consumption. These bacterial genera
are known to predominately contain BSH-positive species (90).
There is therefore good evidence for an effect of oat β-glucan on
the host microbiota with a predicted influence upon those species
that are BSH positive. This would suggest that consumption of
oat β-glucan has the capacity to alter host bile acid profiles.
However, further work is necessary to determine if oat β-glucan
can effectively modulate host bile acid profiles in humans as
predicted by these microbiota analyses.
There is good evidence that BSH-active probiotic
interventions can reduce serum LDL-C providing a direct
link between elevated BSH activity and regulation of host
cholesterol [reviewed in Jones et al. (24) and below]. Whilst the
evidence for a cholesterol-lowering activity of BSH is strong
the precise mechanisms remain elusive and most likely reflect
an alteration in both the physico-chemical properties of bile
acids and the molecular signaling potential of the bile acid pool
for FXR.
Bacterial BSH activity is known to alter the host bile
acid signature through deconjugation of conjugated bile acids.
Unconjugated bile acids have reduced micellular activity and
therefore are less effective mediators of cholesterol absorption in
the host relative to conjugated bile acids (24).
In support of this, administration of a strongly BSH positive
probiotic L. reuteri NCIMB 30242 strain to humans lowered
serum LDL-C and lowered absolute plasma concentrations
of plant sterols (surrogate markers of cholesterol) suggesting
decreased inward transport of cholesterol in the gut (23).
Therefore, elevated bacterial BSH activity is likely to directly
reduce cholesterol uptake from the lumen and this may provide a
general mechanism by which BSH regulates systemic cholesterol
in the host (24). Unconjugated bile acids are alsomore likely to be
eliminated in the feces thereby driving a requirement for de novo
bile acid synthesis and an associated reduction of systemic
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cholesterol (68). Indeed, Joyce et al. (25) showed that expression
of highly active L. salivarius BSH could significantly reduce LDL
cholesterol, total cholesterol and also serum triglycerides in mice.
In humans BSH-active L. acidophilus administered over 6 weeks
could reduce plasma levels of both total cholesterol and LDL-
cholesterol (91). BSH active L. reuteriNCIMB 30242 significantly
reduced LDL-C, total cholesterol in a human randomized
controlled study with elevated free bile acid levels detected in
circulation (22, 23).
The reduced reabsorption of bile acids also reduces their
potential to interact with FXR and may lead to a reduction in
stimulation of FXR. However, unconjugated bile acids also can
act as potent ligands for the FXR and are also the substrates
for further bacterial conversions of bile acids to secondary bile
acids which are also potent FXR agonists. Therefore, another
possible hypothesis is that FXR is activated in the gut by
BSH activity leading to increased FXR signaling in the gut
and expression of the hormone FGF19 by enterocytes leading
to a reduction in hepatic bile acid synthesis. More research
is necessary to understand the chemical and physiological
parameters which dictate whether FXR is stimulated through
local bacterial BSH activity. In the absence of such research
we herein consider the evidence for two potential mechanisms
by which elevated BSH activity may impact host systemic
cholesterol levels. In hypothesis 1 FXR is not activated and
de novo bile acid synthesis is increased. In hypothesis 2 FXR
is activated and FGF19 is elevated resulting in a reduction in
bile acid synthesis and an increase in other mechanisms by
which cholesterol levels are potentially modulated in the host.
Given a number of recent studies which show a decrease in
FXR activation in the gut following administration of BSH-active
probiotics we favor hypothesis 1 as most likely to represent a
scenario in which BSH activity is increased in the gut microbiota
following dietary interventions (as is potentially the case for
β-glucan consumption).
Hypothesis 1: Elevated Bacterial BSH Activity Can
Reduce Engagement of FXR in the Intestine, Increase
Bile Acid Excretion and Increase de novo Synthesis
of Bile Acids in the Liver (Figure 1)
Conjugated bile acids are actively reabsorbed via specific
transport systems into enterocytes in the ileum whereas
unconjugated bile acids are not subject to this specific reuptake
system and are passively absorbed at a lower rate (92). BSH
activity decreases the levels of conjugated bile acids which can be
actively transported and recent in vivo evidence suggests that the
resulting deconjugated bile acids are less efficiently reabsorbed
into enterocytes (93). Unconjugated bile acids then enter the
colon where conversions to secondary bile acids can take place
(94) or are excreted in feces. As the FXR is an intracellular nuclear
receptor lower levels of cellular adsorption of bile acids will lead
to a lowering of FXR activation in the terminal ileum.
In support of this hypothesis it has been shown that
monocolonization of germ-free rats with BSH-active bacterial
species significantly promotes fecal excretion of bile acids (95).
More recently, oral inoculation of rodent models with BSH-
producing probiotic bacteria was shown to reduce intestinal FXR
activation relative to controls in tandem with an alteration of
local bile acid profiles. Inoculation of mice with a highly BSH-
active polybiotic mixture of organisms (VSL#3) significantly
reduced FGF15 (a marker of FXR activation) and increased
expression of hepatic Cyp7a1 and Cyp8b1 and increased bile
acid synthesis (93) (see Figure 1). In a separate study oral
administration of L. plantarum CCFM8661 to mice induced
similar effects; inhibition of the FXR-FGF axis, elevated Cyp7a1
expression and elevated bile acid synthesis (96). In another study
in mice administered a high fat diet oral inoculation with BSH-
active Lb. rhamnosus LGG reduced serum cholesterol in concert
with a downregulation in FXR transcription in the liver and
increased expression of hepaticCyp7a1 (but notCyp8b1) (97). An
earlier study also linked the cholesterol-lowering effect of a Lb.
plantarum probiotic strain to an increase in expression of Cyp7a1
in mice, indicative of downregulation of FXR-mediated feedback
(98). Furthermore, a BSH-active probiotic Lb. reuteri NCIMB
30242 has been shown to reduce serum LDL-C in humans with a
concomitant increase in total bile acid levels (99). As bile acids are
synthesized from cholesterol, increased de novo synthesis of bile
acids contributes to cholesterol catabolism in the host leading to
a lowering of systemic cholesterol levels (68).
Another nuclear receptor, LXR, is indirectly repressed by
the FXR. Therefore, another consequence of reduced FXR
signaling is an elevation of LXR activity. This stimulation of
LXR leads to an increase in expression of the cholesterol efflux
system ABCG5/8 in enterocytes (100) and increased excretion
of cholesterol (54, 101). A recent study demonstrated that the
BSH-active probiotic strain Lactobacillus plantarum LRCC 5273
reduces serum cholesterol in mice along with an increase in
expression of Cyp7A1, an increase in both hepatic and gut LXR
activity and elevated expression of gastrointestinal ABCG5/8
allied with a decrease in expression of the gene encoding NPC1L1
(a cholesterol uptake system) (102). The authors propose a model
in which elevated BSH activity promotes TICEmediated through
LXR activation which involves elevated excretion of cholesterol
from the system and reduced cellular uptake (102). In support
of this another study in mice demonstrated that an increase in
BSH activity in the lumen can increase transcription of Abcg5/8
concomitant with a reduction in serum cholesterol (25).
Whilst bile acid synthesis is controlled by the gastrointestinal-
hepatic FXR-FGF axis another mechanism of feedback inhibition
is mediated directly via circulating bile acids. Bile acids entering
the enterohepatic circulation have the potential to directly
influence FXR signaling in the liver, a process which influences
de novo bile acid synthesis and cholesterol metabolism (103).
A consequence of the elevated excretion of bile acids in feces
as outlined above may be reduced re-circulation of bile acids
and downregulation of liver FXR activity (24). Downregulation
of FXR leads to reduction in SHP and consequently elevated
activity of LXR (24). Indeed the recent study cited above suggests
that elevated BSH activity in the gut results in elevated LXR
expression in the liver in mice (102). The consequences of
reduced hepatic FXR signaling include increased expression of
Cyp7A1 and therefore increased de novo bile acid synthesis.
In addition, LXR activation leads to the expression of hepatic
ABCG5/8 that promotes cholesterol excretion into bile (104) and
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FIGURE 1 | A number of studies suggest that an increase in microbial BSH activity results in a reduction in stimulation of intestinal FXR. (A) Conjugated bile acids
(C-BA) are rapidly absorbed in the terminal ileum but BSH activity reduces the amounts of C-BA locally leading to decreased entry of bile acids (BA) into the cell and
reduced engagement of Farnesoid X receptor (FXR). Reduced FXR potentiates the capacity for LXR to become activated and studies show that liver orphan receptor
(LXR) activation stimulates the Transintestinal Cholesterol Excretion (TICE) pathway in the gut leading to net cholesterol excretion. (B) Reduced engagement of FXR in
the ileum reduces fibroblast growth factor 15 (in mice) or 19 (in humans) (FGF15/19) preventing feedback inhibition of Cyp7A1 and increasing de novo synthesis of bile
acids from cholesterol thereby reducing systemic cholesterol levels. (C) Increased excretion of bile acids reduces hepatic signaling to FXR which results in increased
potential for activation of LXR and elevated expression of Abcg5/8 allowing for excretion of cholesterol into the bile.
plays a significant role in the regulation of systemic cholesterol
levels (105).
Hypothesis 2: Gastrointestinal FXR Is Activated
Through Increased Generation of Unconjugated Bile
Acids by Microbial BSH Activity, FGF19 Is Elevated
Leading to Downregulation of Hepatic Bile Acid
Synthesis and Upregulation of RCT and TICE
(Figure 2)
Whilst both conjugated and unconjugated bile acids can activate
the FXR, unconjugated bile acids generated through elevated
bacterial BSH activity have a greater ability to enter target
cells without a specific transport mechanism (106). There
is evidence that FXR is activated via BSH activity in the
gut. One study indicates that administration of a BSH-active
probiotic, Lb. reuteri NCIMB 30242 to humans lowers LDL-C
with levels of FGF19 trending toward an increase (though the
increase was not statistically significant). Furthermore, somewhat
counterintuitively, there was evidence for an increase in bile
acid synthesis in subjects receiving the probiotic so it is difficult
to determine whether the FXR-FGF axis was indeed engaged
in this study (99). This is in contrast to numerous studies
in animals indicating the opposite effect (see mechanism 1).
Therefore, further human intervention studies are needed to
determine whether FXR may be stimulated by microbial BSH
activity in humans. Other studies demonstrate that a reduction
in BSH activity through administration of antibiotics (107) or
the antioxidant Tempol (108) decreases gut bacterial BSH activity
leading to a reduction in gastrointestinal FXR signaling in mice.
The corollary of these findings would suggest that a physiological
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FIGURE 2 | Under specific circumstances which remain unclear the Farnesoid X receptor (FXR) may be stimulated in the gastrointestinal tract. There is some
evidence from a single human probiotic study that FXR may be stimulated through BSH activity but further studies are warranted. (A) In a model where gastrointestinal
FXR is stimulated unconjugated bile acids (UC-BA) may access the FXR through non-specific passage through cell membranes. (B) There is good evidence that
intestinal FXR activation promotes the Transintestinal Cholesterol Excretion (TICE) system for the net efflux of cholesterol into the feces. FXR activation leads to
elevated intestinal production of FGF15/19 which feeds back to inhibit bile acid synthesis. Via a process that involves FXR this results in a net reduction in hydrophobic
BA species but a relative increase in hydrophilic BA species which are released into the small intestine. As hydrophilic BAs poorly associate with cholesterol this may
reduce cellular uptake of cholesterol in the gut. (C) There is also good evidence that elevated hepatic FXR activation increases systemic reverse cholesterol transport
(RCT) for the mobilization of cholesterol from macrophages (as HDL-C) to the liver for excretion. (D) There is evidence to suggest that engagement of the FXR reduces
the secretion of VLDL into the circulation thereby reducing the systemic circulation of this atherogenic molecule. (E) There is also evidence to suggest that
engagement of the FXR increases the uptake of LDL into the liver from the circulation thereby reducing the systemic circulation of this atherogenic molecule. (F) Finally,
there is evidence to suggest that FXR activation increases hepatic ABCG5/8 with potential to promote biliary secretion of cholesterol.
role of microbial BSH is to enhance FXR signaling in the gut
(106, 108). However, the effects of Tempol or antibiotics upon
the microbiota are so profound in these experiments, that it
is difficult to equate these results to those expected following
consumption of oat β-glucan where subtle increases in BSH
activity akin to probiotic treatments, are expected.
There is significant evidence to support a role for FXR
signaling in cholesterol homeostasis. However, most of this
evidence has been generated through the use of potent FXR-
agonists or through experiments using knock-out mice. There
is relatively little evidence directly linking these effects to
microbiota changes. Oral delivery of FXR agonists has been
shown to decrease systemic LDL-C or non-HDL-C (68, 69) and
to decrease atherosclerotic plaque formation in mouse models of
atherosclerosis (66, 68, 69). Furthermore, mice deleted in FXR
display hypercholesterolemia (23, 50, 109). The mechanisms by
which the FXR regulates systemic cholesterol metabolism are
thought to include regulation of cellular LDL-C uptake, reduction
in plasma VLDL, modulation of plasma HDL-C levels, regulation
of reverse cholesterol transport (RCT) and possible regulation
of trans-intestinal cholesterol excretion (TICE) [reviewed in Li
and Chiang (27)]. Studies in animal models suggest that FXR
agonists can lower plasma VLDL levels (110, 111). Recent studies
demonstrate that FXR agonists reduce hepatic secretion of VLDL
by suppressing expression of PLA2G12B, a protein involved in
assembly and secretion of potentially atherogenic VLDL (111).
In addition, FXR knockout mice demonstrate reduced clearance
of plasma HDL-C and further studies suggest that hepatic FXR
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activation increases RCT from macrophages and fecal excretion
of cholesterol (69, 100).
The cholesterol transport system ABCG5/8 is positively
regulated by FXR (in addition to regulation via LXR) and
there is evidence to suggest that FXR activation increases
hepatic ABCG5/8 with potential to promote biliary secretion
of cholesterol [reviewed in Li and Chiang (27)]. ABCG5/8 is
also expressed in enterocytes where it plays a significant role in
the elimination of cholesterol into the gut lumen through TICE
[reviewed in de Boer et al. (54)]. In mice engagement of hepatic
FXR using an agonist significantly reduced serum cholesterol,
increased RCT and increased the hydrophilic bile acid pool. As
hydrophilic bile acids less efficiently associate with cholesterol
this was thought to be a factor which reduced intestinal
absorption of cholesterol thereby lowering systemic cholesterol
levels (112). Other studies have indicated that FXR agonists
stimulate TICE to significantly increase cholesterol excretion.
TICE was not evident in knock-out mice lacking intestinal FXR
indicating that this pathway is highly dependent upon FXR
activation in the gut (101). However it should be appreciated that
activation of LXR in the gut (allied to downregulation of FXR)
can also induce the TICE system (see mechanism 1) (101).
Propionate and Other Short-Chain Fatty
Acids (SCFA)
SCFAs are microbial metabolites that are particularly associated
with fermentation of dietary fibers. Exposure of fecal bacteria to
oat bran fractions using in vitromodel systems has demonstrated
an ability of oat β-glucan to stimulate SCFA production by
the gut microbiota (81, 113–115). In many of the studies
propionate predominated amongst the SCFAs stimulated by oat
bran fermentation (81, 113, 114). Animal studies support the
finding that oat fermentation alters the microbiota and elevates
SCFA production in the colon. In mice, oat-derived β-glucan
consumption led to an alteration to the fecal microbiota and
an elevated level of propionate in the colon (84) whilst in
another recent study in ApoE− mice feeding of oat β-glucan
led to elevated n-butyrate levels (32). In rats, oat β-glucan
feeding also increased overall SCFA levels (87, 116, 117). Similarly
porcine feeding studies indicate an increase in overall SCFA levels
following consumption of oat β-glucans or similar feed additives
(118, 119) with elevated butyrate in particular being evident in
some studies (120, 121). In one study SCFAs were lower in pigs
fed oat products relative to the control (122). However, overall the
animal feeding studies suggest an influence of oat β-glucan on the
gut microbiota which results in an elevated production of SCFAs.
Whilst studies have examined the effects of oats on human-
derived microbial populations in ex vivo models, relatively few
studies have examined the effects of oat consumption on SCFA
production in human intervention studies. In a randomized
clinical trial oat β-glucan resulted in reduced cholesterol
concomitant with an increase in total SCFA and in particular
butyrate (123). A similar study determined that total SCFAs were
elevated in subjects fed a β-glucan rich oat bran for 8 weeks (124).
Another randomized clinical trial demonstrated the efficacy of
bran β-glucans in lowering cholesterol with effects linked to an
increase in SCFAs (in particular propionate) concomitant with
changes to the microbiota (125). Another study demonstrated
an increase in fecal SCFAs in subjects consuming a high Mw
barley β-glucan in concert with an increase in fecal bile acid
excretion (126). The same effects were not seen in subjects
consuming a low Mw barley β-glucan (126). In contrast, a
recent study which investigated the effects of a whole grain oat
granola upon microbiota markers failed to show an influence
upon fecal SCFA levels despite a significant lowering of TC
and LDL cholesterol levels (19). The authors suggested that
in future studies measurement of circulating SCFAs would be
more informative in order to determine physiologically relevant
systemic effects.
Indeed, as SCFAs are rapidly absorbed by enterocytes in
the gut their presence may be a rather transient marker of
gut microbial activity. In this respect fecal fermentation studies
with controlled human microbiota samples may represent an
accurate measure of the influence of biotic factors on SCFA
production in the gut (as the SCFA will not be absorbed in
this model). A study by Carlson et al. recently demonstrated
that a commercially available source of oat β-glucan significantly
increased propionate production by the microbiota in a human
fecal fermentation system (127). The work confirms other earlier
studies which demonstrated that addition of sources of oat β-
glucan to in vitro microbial fermentation systems can increase
SCFA (in particular propionate) production (81, 114, 128).
The signaling and health-promoting effects of SCFAs are
relatively well-established (129). Luminal propionate engages
specific receptors (GPR41 and GPR43) to influence local
production of hormones, and regulates satiety and intestinal
transit times (129). Propionate and butyrate also mediate anti-
inflammatory effects in the host through interaction with GPR43
expressed in Treg cells (in the case of propionate) or interaction
with GPR109A on dendritic cells (in the case of butyrate) (129,
130). Of the SCFAs, propionate in particular plays a significant
role in modulation of cellular lipid metabolism, resulting in
effects that may be linked to the proposed cholesterol-lowering
effect of propionate (30). However more studies are required
to definitively prove these links and address mechanisms (30).
Exposure of rat hepatocytes to propionate in culture resulted in a
reduction in cellular cholesterol synthesis (131) an effect that was
potentially linked to reductions in acetyl-CoA synthase activity
or acetate uptake, both of which are features of cholesterol
metabolism [reviewed in Hosseini et al. (30)].
A number of studies have proposed an effect of SCFAs
(including propionate) in the lowering of cholesterol markers
in animal or human systems. Positive correlations between the
cholesterol-lowering properties of probiotics and elevated SCFAs
(notably propionate and butyrate) have beenmade inmurine and
rat intervention studies (132, 133). Positive correlations have also
been made between the cholesterol-lowering properties of fibers
other than β-glucan and elevated levels of SCFAs (134, 135).
More direct causal effects can be seen when subjects
either consume dietary SCFAs or they are directly infused.
In rats dietary supplementation with propionate led to a
significant decrease in plasma TC levels (136). A more recent
study demonstrated that dietary feeding of individual SCFAs
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(propionate, acetate or butyrate) was sufficient to lower TC and
non-HDL cholesterol in hypercholesterolaemic hamsters (137).
The effects were correlated with increased bile acid excretion in
the feces and elevated expression of enzymes involved in bile acid
synthesis (137). A recent study demonstrated that oral infusion
of a mixture of acetate, butyrate and propionate can reduce
serum cholesterol levels in pigs (138). In contrast a previous
study in which pigs were infused with propionate directly into
the caecum failed to show a cholesterol-lowering effect (139).
To our knowledge studies investigating the effects of dietary
supplementation with SCFAs on cholesterol levels in humans
are relatively limited. In two separate studies consumption or
infusion of additional dietary propionate did not alter markers of
lipid metabolism (140) or cholesterol (141) in healthy volunteers.
Microbial Exopolysaccharide (EPS) in
Cholesterol Homeostasis
In addition to modulation of bile acid profiles and production
of SCFAs, gut microorganisms can influence the host through
toll-like receptor agonists and other microbial components
(including EPS). EPS is composed of repeating carbohydrate
moieties, either strongly or loosely associated with the
peptidoglycan layer of many lactic acid bacteria (including
Lactobacillus and Bifidobacterium species) (142, 143). Given that
these bacterial populations may be altered by consumption of
oat β-glucans (19) we predict that EPS is likely to play a role
as an effector of microbe-host crosstalk influenced by potential
prebiotic effects of β-glucans. EPS is thought to protect the
bacterial cell from environmental stressors and to improve
survival in the GI tract but also plays a role in microbe-host
interactions [reviewed in Ryan et al. (143)]. Production of EPS
has been associated with the immunoregulatory properties of
specific strains used as probiotics (144) and also plays a role
in lowering of cholesterol. The Pediococcus parvulus strain
2.6 produces an EPS that resembles the structure of oat β-
glucan (143) and the strain has been shown to regulate serum
cholesterol in hypercholesterolaemic volunteers consuming a
fermented beverage made with P. parvulus 2.6 (145). London
et al. showed that a Lactobacillus strain engineered to produce
EPS demonstrated a greater cholesterol-lowering effect in a
mouse model of atherosclerosis than an isogenic non-producer
(146). Furthermore a Lb. mucosae DPC6426 strain which
naturally produces high levels of EPS was capable of reducing
lipid markers (TC and serum triglyceride) in the same model
system (146). EPS extracted from Lactobacillus strains caused
a reduction in triacylglycerol lipid accumulation in an in vitro
adipocyte model and a reduction in levels of triacylglycerol and
cholesterol in murine fat tissue when mice were injected with
EPS. The work demonstrated a role for TLR2 in the cholesterol
and lipid-lowering effects of EPS (147). Overall the data suggest
that alteration to the relative levels and chemical isotypes of
EPS in the GI tract through alterations to the microbiota may
have the potential to modulate host cholesterol metabolism,
potentially through a TLR2-mediated mechanism. However,
further mechanistic studies are required.
Microbial Cholesterol Assimilation and
Metabolism
Numerous bacterial genera found throughout the biosphere
have the capacity to metabolize cholesterol. Genomic approaches
have identified likely mechanisms by which some species can
degrade cholesterol but others remain uncharacterized [reviewed
in Garcia et al. (148) and Bergstrand et al. (149)]. A number
of gut-dwelling bacterial species have the capacity to transport
and/or metabolize cholesterol with the potential mechanisms
being established in Eubacterium coprostanoligenes (148) an
organism that can actively metabolize cholesterol to coprostanol
in the GI tract in animal models (150, 151). Lactobacillus
acidophilus, Lb., casei, and Lb. bulgaricus have been shown to
assimilate cholesterol and to reduce cholesterol to coprostanol
through the activity of a cholesterol reductase (152). Rationally
selected Lactobacillus strains were capable of reducing serum
TC and LDL cholesterol in rats fed a lipid-rich diet, a finding
that correlated with elevated SCFAs and bile acid excretion in
these animals (132). Recent work has identified that Bacteroides
spp. isolated from the gut can produce a compound called
commendamide which has the capacity to degrade cholesterol
and may represent a bacterial adaptation to the gut environment
(153). Human intervention studies have indicated an increase
in Bacteroidetes in humans following consumption of β-glucan
(89), so there is potential for this to represent a mechanism by
which microbiota changes may influence cholesterol metabolism
in the host. More work is necessary to establish the cholesterol-
metabolizing activities of the gut microbiota in health and
disease. However, it is clear that alterations to gut microbial
community structure have the potential to alter this important
physiological function.
CONCLUSIONS AND FUTURE
DIRECTIONS
The significant clinical evidence for the cholesterol-lowering
effects of β-glucan has led health authorities in the US, Europe
and elsewhere to permit health claims attributing a lowering of
CVD risk to consumption of specific amounts (generally 3 g per
day) of β-glucan. The mechanisms by which β-glucan may lower
host cholesterol levels are thought to be linked to an ability to
prevent re-circulation or enhance excretion of bile acids, effects
that are potentially related to the gel-forming properties of β-
glucan. As bile acids are a major repository of cholesterol in
the host this leads to an overall reduction in cholesterol from
the system.
However, in recent years our knowledge of both cholesterol
metabolism and the physiological role of the gut microbiota has
increased significantly. It has become clear that diet (including
consumption of β-glucans) has the potential to significantly
alter the composition of the gut microbiota. In turn studies
have shown that the composition of the gut microbiota is a
major regulator of both cholesterol and bile acid metabolism
in the host. Studies in pigs have shown that β-glucan feeding
alters the ability of intestinal cells to reabsorb bile acids and
also alters the bile acid profile in the host, suggesting that
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changes in the microbiota are concomitant with the cholesterol-
lowering effect (65). Other studies have confirmed an apparent
“prebiotic” effect whereby the microbiota is altered through
consumption of oat β-glucan in a manner that is suggestive of
an ability to alter the bile acid metabolizing potential of the
gut microbial community (19). In the absence of studies which
precisely analyze the effect of β-glucan consumption on both
the microbiota and bile acid profiles we outlined two hypotheses
by which cholesterol metabolism may be impacted by gut
microbiota-mediated alterations (section Mechanisms by Which
Oat β-Glucan May Influence Host Cholesterol Metabolism
Through Alterations in BSH Activity of the Microbiome). We
propose a microbe-centered model in which microbial bile acid
metabolism results in reduced engagement of the host bile acid
receptor FXR, stimulating enhanced de novo bile acid synthesis
and enhanced TICE (Figure 1). Furthermore, in this review we
outline that other microbe-host interactions may contribute to
the cholesterol-lowering effects of β-glucan though stimulation
of SCFA production, cholesterol degradation or via the effects of
microbial EPS.
We propose that future studies should utilize a systems
biology approach toward understanding the complex interplay
between β-glucan, the microbiota and mechanisms in the
host that regulate serum cholesterol levels. Data which links
consumption of β-glucan to bile acid changes in the host and
identifies host metabolic changes (including to levels of FGF19)
will be invaluable for enhancing our understanding of the
mechanisms by which oat β-glucan mediates its cholesterol-
lowering effects.
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